Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy

Bryan W Miller; Jennifer P Morton; Mark Pinese; Grazia Saturno; Nigel B Jamieson; Ewan McGhee; Paul Timpson; Joshua Leach; Lynn McGarry; Emma Shanks; Peter Bailey; David Chang; Karin Oien; Saadia Karim; Amy Au; Colin Steele; Christopher Ross Carter; Colin McKay; Kurt Anderson; Thomas R Jeffry Evans; Richard Marais; Caroline Springer; Andrew Biankin; Janine T Erler; Owen J Sansom

doi:10.15252/emmm.201404827

Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy

Bryan W Miller, Jennifer P Morton, Mark Pinese, Grazia Saturno, Nigel B Jamieson, Ewan McGhee, Paul Timpson, Joshua Leach, Lynn McGarry, Emma Shanks, Peter Bailey, David Chang, Karin Oien, Saadia Karim, Amy Au, Colin Steele, Christopher Ross Carter, Colin McKay, Kurt Anderson, Thomas R Jeffry EvansRichard Marais, Caroline Springer, Andrew Biankin, Janine T Erler, Owen J Sansom

137 Citations (Scopus)

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of cancer-related mortality. Despite significant advances made in the treatment of other cancers, current chemotherapies offer little survival benefit in this disease. Pancreaticoduodenectomy offers patients the possibility of a cure, but most will die of recurrent or metastatic disease. Hence, preventing metastatic disease in these patients would be of significant benefit. Using principal component analysis (PCA), we identified a LOX/hypoxia signature associated with poor patient survival in resectable patients. We found that LOX expression is upregulated in metastatic tumors from Pdx1-Cre Kras(G12D/+) Trp53(R172H/+) (KPC) mice and that inhibition of LOX in these mice suppressed metastasis. Mechanistically, LOX inhibition suppressed both migration and invasion of KPC cells. LOX inhibition also synergized with gemcitabine to kill tumors and significantly prolonged tumor-free survival in KPC mice with early-stage tumors. This was associated with stromal alterations, including increased vasculature and decreased fibrillar collagen, and increased infiltration of macrophages and neutrophils into tumors. Therefore, LOX inhibition is able to reverse many of the features that make PDAC inherently refractory to conventional therapies and targeting LOX could improve outcome in surgically resectable disease.

Original language	English
Journal	EMBO Molecular Medicine
Volume	7
Issue number	8
Pages (from-to)	1063-1076
Number of pages	13
ISSN	1757-4676
DOIs	https://doi.org/10.15252/emmm.201404827
Publication status	Published - 1 Aug 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.15252/emmm.201404827

Cite this

Miller, B. W., Morton, J. P., Pinese, M., Saturno, G., Jamieson, N. B., McGhee, E., Timpson, P., Leach, J., McGarry, L., Shanks, E., Bailey, P., Chang, D., Oien, K., Karim, S., Au, A., Steele, C., Carter, C. R., McKay, C., Anderson, K., ... Sansom, O. J. (2015). Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy. EMBO Molecular Medicine, 7(8), 1063-1076. https://doi.org/10.15252/emmm.201404827

Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy. / Miller, Bryan W; Morton, Jennifer P; Pinese, Mark et al.
In: EMBO Molecular Medicine, Vol. 7, No. 8, 01.08.2015, p. 1063-1076.

Research output: Contribution to journal › Journal article › Research › peer-review

Miller, BW, Morton, JP, Pinese, M, Saturno, G, Jamieson, NB, McGhee, E, Timpson, P, Leach, J, McGarry, L, Shanks, E, Bailey, P, Chang, D, Oien, K, Karim, S, Au, A, Steele, C, Carter, CR, McKay, C, Anderson, K, Evans, TRJ, Marais, R, Springer, C, Biankin, A, Erler, JT & Sansom, OJ 2015, 'Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy', EMBO Molecular Medicine, vol. 7, no. 8, pp. 1063-1076. https://doi.org/10.15252/emmm.201404827

@article{6655871630a54186a57b6ff4a84aae42,

title = "Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy",

abstract = "Pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of cancer-related mortality. Despite significant advances made in the treatment of other cancers, current chemotherapies offer little survival benefit in this disease. Pancreaticoduodenectomy offers patients the possibility of a cure, but most will die of recurrent or metastatic disease. Hence, preventing metastatic disease in these patients would be of significant benefit. Using principal component analysis (PCA), we identified a LOX/hypoxia signature associated with poor patient survival in resectable patients. We found that LOX expression is upregulated in metastatic tumors from Pdx1-Cre Kras(G12D/+) Trp53(R172H/+) (KPC) mice and that inhibition of LOX in these mice suppressed metastasis. Mechanistically, LOX inhibition suppressed both migration and invasion of KPC cells. LOX inhibition also synergized with gemcitabine to kill tumors and significantly prolonged tumor-free survival in KPC mice with early-stage tumors. This was associated with stromal alterations, including increased vasculature and decreased fibrillar collagen, and increased infiltration of macrophages and neutrophils into tumors. Therefore, LOX inhibition is able to reverse many of the features that make PDAC inherently refractory to conventional therapies and targeting LOX could improve outcome in surgically resectable disease.",

author = "Miller, {Bryan W} and Morton, {Jennifer P} and Mark Pinese and Grazia Saturno and Jamieson, {Nigel B} and Ewan McGhee and Paul Timpson and Joshua Leach and Lynn McGarry and Emma Shanks and Peter Bailey and David Chang and Karin Oien and Saadia Karim and Amy Au and Colin Steele and Carter, {Christopher Ross} and Colin McKay and Kurt Anderson and Evans, {Thomas R Jeffry} and Richard Marais and Caroline Springer and Andrew Biankin and Erler, {Janine T} and Sansom, {Owen J}",

note = "{\textcopyright} 2015 Cancer Research UK Beatson Institute. Published under the terms of the CC BY 4.0 license.",

year = "2015",

month = aug,

day = "1",

doi = "10.15252/emmm.201404827",

language = "English",

volume = "7",

pages = "1063--1076",

journal = "EMBO Molecular Medicine",

issn = "1757-4676",

publisher = "Wiley-Blackwell",

number = "8",

}

TY - JOUR

T1 - Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly

T2 - inhibition of LOX abrogates metastasis and enhances drug efficacy

AU - Miller, Bryan W

AU - Morton, Jennifer P

AU - Pinese, Mark

AU - Saturno, Grazia

AU - Jamieson, Nigel B

AU - McGhee, Ewan

AU - Timpson, Paul

AU - Leach, Joshua

AU - McGarry, Lynn

AU - Shanks, Emma

AU - Bailey, Peter

AU - Chang, David

AU - Oien, Karin

AU - Karim, Saadia

AU - Au, Amy

AU - Steele, Colin

AU - Carter, Christopher Ross

AU - McKay, Colin

AU - Anderson, Kurt

AU - Evans, Thomas R Jeffry

AU - Marais, Richard

AU - Springer, Caroline

AU - Biankin, Andrew

AU - Erler, Janine T

AU - Sansom, Owen J

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of cancer-related mortality. Despite significant advances made in the treatment of other cancers, current chemotherapies offer little survival benefit in this disease. Pancreaticoduodenectomy offers patients the possibility of a cure, but most will die of recurrent or metastatic disease. Hence, preventing metastatic disease in these patients would be of significant benefit. Using principal component analysis (PCA), we identified a LOX/hypoxia signature associated with poor patient survival in resectable patients. We found that LOX expression is upregulated in metastatic tumors from Pdx1-Cre Kras(G12D/+) Trp53(R172H/+) (KPC) mice and that inhibition of LOX in these mice suppressed metastasis. Mechanistically, LOX inhibition suppressed both migration and invasion of KPC cells. LOX inhibition also synergized with gemcitabine to kill tumors and significantly prolonged tumor-free survival in KPC mice with early-stage tumors. This was associated with stromal alterations, including increased vasculature and decreased fibrillar collagen, and increased infiltration of macrophages and neutrophils into tumors. Therefore, LOX inhibition is able to reverse many of the features that make PDAC inherently refractory to conventional therapies and targeting LOX could improve outcome in surgically resectable disease.

AB - Pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of cancer-related mortality. Despite significant advances made in the treatment of other cancers, current chemotherapies offer little survival benefit in this disease. Pancreaticoduodenectomy offers patients the possibility of a cure, but most will die of recurrent or metastatic disease. Hence, preventing metastatic disease in these patients would be of significant benefit. Using principal component analysis (PCA), we identified a LOX/hypoxia signature associated with poor patient survival in resectable patients. We found that LOX expression is upregulated in metastatic tumors from Pdx1-Cre Kras(G12D/+) Trp53(R172H/+) (KPC) mice and that inhibition of LOX in these mice suppressed metastasis. Mechanistically, LOX inhibition suppressed both migration and invasion of KPC cells. LOX inhibition also synergized with gemcitabine to kill tumors and significantly prolonged tumor-free survival in KPC mice with early-stage tumors. This was associated with stromal alterations, including increased vasculature and decreased fibrillar collagen, and increased infiltration of macrophages and neutrophils into tumors. Therefore, LOX inhibition is able to reverse many of the features that make PDAC inherently refractory to conventional therapies and targeting LOX could improve outcome in surgically resectable disease.

U2 - 10.15252/emmm.201404827

DO - 10.15252/emmm.201404827

M3 - Journal article

C2 - 26077591

SN - 1757-4676

VL - 7

SP - 1063

EP - 1076

JO - EMBO Molecular Medicine

JF - EMBO Molecular Medicine

IS - 8

ER -

Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this